Commentary

Annals of Internal Medicine

Volumn 159, Issue 6, 2013, Pages

  Bender, Bradley S ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; MICROBICIDE; TENOFOVIR;

ANTIVIRAL RESISTANCE; CIRCUMCISION; COST EFFECTIVENESS ANALYSIS; DIRECTLY OBSERVED THERAPY; HETEROSEXUAL MALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MEN WHO HAVE SEX WITH MEN; NONHUMAN; NOTE; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 84884180796     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-159-6-201309170-02008     Document Type: Note

References (4)

1. Centers for Disease Control and Prevention. High-impact HIV prevention: CDC's approach to reducing HIV infections in the United States. www.cdc.gov/hiv/policies/hip.html (accessed 24 Jul 13).
2. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99.
3. Baeten JM, Donnell D, Ndase P, et al; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.
4. Centers for Disease Control and Prevention. HIV surveillance report, 2011; vol. 23. Published February 2013. www.cdc.gov/hiv/topics/ surveillance/resources/reports/ (accessed 24 Jul 13).